BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 17264789)

  • 1. Oral capecitabine (Xeloda) in cancer treatment.
    Doyle DP; Engelking C
    Nurse Pract; 2007 Feb; 32(2):18-21. PubMed ID: 17264789
    [No Abstract]   [Full Text] [Related]  

  • 2. [The potential of capecitabine (Xeloda) in the treatment of disseminated solid tumors].
    Moiseenko VM; Semenova AI; Orlova RV
    Vopr Onkol; 2001; 47(1):112-9. PubMed ID: 11317529
    [No Abstract]   [Full Text] [Related]  

  • 3. How the new oral antineoplastics affect nursing practice: capecitabine serves to illustrate.
    Szetela AB; Gibson DE
    Am J Nurs; 2007 Dec; 107(12):40-8; quiz 48-9. PubMed ID: 18049060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Xeloda in colorectal cancer.
    Cassidy J
    Int J Clin Pract; 2001 Jun; 55(5):326-8. PubMed ID: 11452682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capecitabine: fulfilling the promise of oral chemotherapy.
    Hwang JJ; Marshall JL
    Expert Opin Pharmacother; 2002 Jun; 3(6):733-43. PubMed ID: 12036413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incorporating oral capecitabine into the treatment of breast cancer. Introduction.
    Seidman AD; Aapro M
    Oncologist; 2002; 7 Suppl 6():1-3. PubMed ID: 12454313
    [No Abstract]   [Full Text] [Related]  

  • 7. Implications of capecitabine (Xeloda) for cancer nursing practice.
    Gerbrecht BM; Kangas T
    Eur J Oncol Nurs; 2004; 8 Suppl 1():S63-71. PubMed ID: 15341883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On prejudice and facts and choices.
    Köhne CH; Folprecht G
    Ann Oncol; 2006 Feb; 17(2):185-7. PubMed ID: 16428244
    [No Abstract]   [Full Text] [Related]  

  • 9. Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda).
    Marsé H; Van Cutsem E; Grothey A; Valverde S
    Eur J Oncol Nurs; 2004; 8 Suppl 1():S16-30. PubMed ID: 15341879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Oral capecitabine therapy: experience and developments at the Milano Cancer Institute].
    Longo F; Mansueto G
    Tumori; 2004; 90(1):suppl 17-27. PubMed ID: 15143996
    [No Abstract]   [Full Text] [Related]  

  • 11. Implementation of capecitabine (Xeloda) into a cancer centre: UK experience.
    Faithfull S; Deery P
    Eur J Oncol Nurs; 2004; 8 Suppl 1():S54-62. PubMed ID: 15341882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study.
    Kosmas C; Kallistratos MS; Kopterides P; Syrios J; Skopelitis H; Mylonakis N; Karabelis A; Tsavaris N
    J Cancer Res Clin Oncol; 2008 Jan; 134(1):75-82. PubMed ID: 17636329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral versus intravenous fluoropyrimidines for advanced colorectal cancer: by either route, it's all the same.
    Mayer RJ
    J Clin Oncol; 2001 Nov; 19(21):4093-6. PubMed ID: 11689576
    [No Abstract]   [Full Text] [Related]  

  • 14. Capecitabine: the new generation of fluoropyrimidines in colorectal cancer.
    Iqbal S; Lenz HJ
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):947-55. PubMed ID: 15606325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda).
    Lassere Y; Hoff P
    Eur J Oncol Nurs; 2004; 8 Suppl 1():S31-40. PubMed ID: 15341880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluoropyrimidines: a critical evaluation.
    Brito RA; Medgyesy D; Zukowski TH; Royce ME; Ravandi-Kashani F; Hoff PM; Pazdur R
    Oncology; 1999 Jul; 57 Suppl 1():2-8. PubMed ID: 10436410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of and clinical experience with capecitabine (Xeloda) in the treatment of solid tumours.
    Sternberg CN; Reichardt P; Holland M
    Eur J Oncol Nurs; 2004; 8 Suppl 1():S4-15. PubMed ID: 15341878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral fluoropyrimidines in cancer treatment.
    Lewis NL; Meropol NJ
    Cancer Invest; 2000; 18(8):747-60. PubMed ID: 11107445
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer.
    Aprile G; Mazzer M; Moroso S; Puglisi F
    Anticancer Drugs; 2009 Apr; 20(4):217-29. PubMed ID: 19247178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Capecitabine in colorectal carcinoma: news from ASCO 2008]].
    Longo F; Mansueto G
    Tumori; 2008; 94(4):suppl 15-23. PubMed ID: 18822712
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.